𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Adjuvant IFN-α-2b for high-risk melanoma patients recommended

Book ID
120866748
Publisher
Adis International Limited (now part of Wolters Kluwer Health)
Year
2001
Weight
122 KB
Volume
&NA;
Category
Article
ISSN
1173-8324

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetic/pharmacodynamic analysis
Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma
✍ A. I. Daud; C. Xu; W.-J. Hwu; P. Urbas; S. Andrews; N. E. Papadopoulos; L. C. Fl 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 369 KB

## Purpose High-dose pegylated interferon α-2b (peginterferon α-2b) significantly decreased disease recurrence in patients with resected stage III melanoma in a clinical study. We investigated the pharmacokinetics (PK) and safety of high-dose peginterferon α-2b in patients with high-risk melanoma.

The feasibility of adjuvant interferon α
The feasibility of adjuvant interferon α-2b in children with high-risk melanoma
✍ Fariba Navid; Wayne L. Furman; Martin Fleming; Bhaskar N. Rao; Sandra Kovach; Ca 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract ## BACKGROUND It has been shown that induction high‐dose interferon α‐2b (IFN‐α‐2b) followed by maintenance therapy improves recurrence‐free survival in adults with high‐risk, resected melanoma. In this study, the feasibility and toxicity of this regimen were evaluated in newly diagnos